PRODUCT

Cagrilintide + Semaglutide (10 mg Blend)

No short description available.

Quickstart Highlights

Cagrilintide + Semaglutide is a dual‑agonist combination blending an amylin analog (cagrilintide) with a GLP‑1 receptor agonist (Semaglutide). Clinical trials demonstrate superior weight reduction versus either agent alone, with the combination targeting complementary satiety pathways[1][2]. This educational protocol presents a once‑weekly subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total (1.67 mg/mL each peptide).
Typical weekly range: 0.25–2.4 mg of each peptide once weekly (gradual titration over 16+ weeks).
Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg each peptide on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days; avoid freeze–thaw cycles.

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until fully dissolved (do not shake).
Label with date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light; use within 30 days [7] .
Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 30 days[7].

Protocol Overview

Goal:Support significant weight reduction through dual amylin + GLP‑1 receptor agonism[1][2].
Schedule:Weekly subcutaneous injections for 16+ weeks (maintenance thereafter).
Dose Range:0.25–2.4 mg each peptide weekly with gradual titration.
Reconstitution:3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; use within 30 days.

Dosage Protocols

Start:0.25 mg each weekly for 4 weeks[3].
Target:2.4 mg each weekly by Week 17+[1].
Frequency:Once per week (subcutaneous), same day each week.
Timing:Any consistent time; rotate injection sites.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation[6].
Inject slowly; wait a few seconds before withdrawing the needle.
Document weekly dose and site rotation to maintain consistency.
Higher doses may increase GI side effects (nausea, reduced appetite); titrate gradually[3].

How It Works

Cagrilintide is a long‑acting amylin analog that reduces appetite via central satiety pathways, while Semaglutide activates GLP‑1 receptors to enhance glucose‑dependent insulin secretion and suppress glucagon[4][5]. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP‑1 enhances pancreatic β‑cell function and central appetite suppression[1]. Clinical trials of the co‑administered regimen (CagriSema) show greater body‑weight reduction than either agent alone[2].

Lifestyle Factors

Pair with a balanced, protein‑forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep and stress management to support adherence and recovery.
Stay hydrated and eat slowly to reduce GI discomfort.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8].
Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[6].
For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.

Benefits and Side Effects

Benefits

Weight reduction: Phase 2 trials report mean body‑weight loss of ~15–17% at 32 weeks with the combination, exceeding Semaglutide monotherapy[2].
Glycemic control: In type 2 diabetes, HbA1c reductions were observed alongside weight loss[1].

Side Effects

GI tolerability: Nausea, vomiting, and diarrhea are the most common adverse events; gradual titration minimizes severity[3].
Injection‑site reactions: Mild and transient in clinical reports.

Cagrilintide + Semaglutide (10 mg Blend)

Resources

Categories

Company